Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:6:275-86.
doi: 10.4137/CMO.S7245. Epub 2012 Jul 30.

Ipilimumab pharmacotherapy in patients with metastatic melanoma

Joanne M Jeter  1 , Lee D Cranmer, Evan M Hersh
Affiliations

Ipilimumab pharmacotherapy in patients with metastatic melanoma

Joanne M Jeter et al. Clin Med Insights Oncol. 2012.

Abstract

Immune augmentation with ipilimumab, an anti-CTLA-4 monoclonal antibody, has joined the ranks of approved immunologic agents for the treatment of metastatic melanoma. Phase III studies of ipilimumab in metastatic melanoma have demonstrated an overall survival advantage as compared to other approved and investigational therapies. However, the adverse effects associated with this medication are unique and often require management with steroids or other immunosuppressants. In addition, the time to response differs with ipilimumab as compared to traditional chemotherapy, and alternative means of assessment of response have been proposed. In this review, we will summarize the basic science of this treatment, its preclinical evaluation, and the clinical trials leading to its approval. We will also discuss the details regarding its use, assessment of response to this drug and other immune-related therapies, and further directions for investigation.

Keywords: CTLA-4; Yervoy™; ipilimumab; melanoma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Dutcher JP, Creekmore S, Weiss GR, et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol. 1989;7(4):477. - PubMed
    1. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271(12):907. - PubMed
    1. Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 1982;307(15):913. - PubMed
    1. Cranmer LD, Hersh E. The role of the CTLA-4 blockade in the treatment of malignant melanoma. Cancer Investigation. 2007;25:613–31. - PubMed
    1. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000 Jul 17;192(2):303–10. - PMC - PubMed

LinkOut - more resources